Previous 10 | Next 10 |
New PERSIST-AVR study results and SURE-AVR registry data analysis underscore utility of Perceval as a minimally invasive surgical approach for patients with aortic valve stenosis LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today ann...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its third quarter 2...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Baird 2020 Global Healthcare Conference on Thursday, September 10 at 9:05 a.m. Eastern Time. The discussion will be availab...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) announces positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoiet...
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term ...
Shares of LivaNova (LIVN) have been moving sideways. Learn the exact price point to buy or sell the stock. Shares of LivaNova ( LIVN ) have been moving sideways, within a trading range since April and a rectangle pattern has formed. LivaNova is a medical device firm primarily focused on c...
LivaNova PLC (LIVN) Q2 2020 Earnings Conference Call July 29, 2020 07:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development Damien McDonald - Chief Executive Officer Thad Huston - Chief Financial Officer Melissa Farina - Vice President of ...
The following slide deck was published by LivaNova PLC in conjunction with their 2020 Q2 earnings Read more ...
LivaNova PLC (NASDAQ: LIVN ) : Q2 Non-GAAP EPS of -$0.15 beats by $0.15 ; GAAP EPS of -$1.81 misses by $1.14 . Revenue of $182.2M (-34.3% Y/Y) beats by $12.46M . Press Release More news on: LivaNova PLC, Earnings news and commentary, Healthcare stocks news,
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020. For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million, a decrease of 34.3 percent on a reported basi...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. ...
2024-06-06 11:00:14 ET Rick Wise from Stifel Nicolaus issued a price target of $70.00 for LIVN on 2024-06-06 09:52:00. The adjusted price target was set to $70.00. At the time of the announcement, LIVN was trading at $53.16. The overall price target consensus is at $69.5...